

Emily Figueiredo Vieira Neves Yuki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1821473/publications.pdf>

Version: 2024-02-01

19
papers

426
citations

949033

11
h-index

939365

18
g-index

21
all docs

21
docs citations

21
times ranked

475
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. <i>Rheumatology</i> , 2022, 61, 3351-3361.	0.9	13
2	Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 562-571.	1.5	25
3	Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. <i>Lancet Rheumatology</i> , The, 2022, 4, e113-e124.	2.2	24
4	Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 49-56.	2.0	18
5	Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 710-719.	0.5	16
6	Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. <i>Journal of Applied Physiology</i> , 2022, 132, 682-688.	1.2	2
7	Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity. <i>Clinical Rheumatology</i> , 2022, 41, 2079-2089.	1.0	7
8	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1036-1043.	0.5	30
9	Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. <i>Lancet HIV</i> , 2022, 9, e323-e331.	2.1	36
10	SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. <i>Rheumatology</i> , 2022, 61, S1169-S1174.	0.9	9
11	Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 889-897.	0.5	42
12	Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 248-259.	0.5	18
13	One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. <i>Lupus</i> , 2021, 30, 956-964.	0.8	3
14	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. <i>Nature Medicine</i> , 2021, 27, 1744-1751.	15.2	148
15	Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. <i>Lupus</i> , 2021, 30, 1915-1922.	0.8	3
16	Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010002.	1.3	5
17	Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. <i>Lupus</i> , 2020, 29, 560-568.	0.8	18
18	Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area. <i>Clinics</i> , 2020, 75, e1870.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Longitudinal Extensive Transverse Myelitis and Central Diabetes Insipidus. Journal of Clinical Rheumatology, 2017, 23, 122-124.	0.5	0